Viatris Tipped To Knock Out Crucial Eylea Dosing Patents In US
Lower Preponderance-Of-The-Evidence Standard May Favor Mylan
A senior analyst for a major investment bank has listened to oral arguments in Viatris’ legal tussle vs. Regeneron over two key US dosing patents shielding the originator’s Eylea (aflibercept) blockbuster.
